ViroGates AS (OCSE:VIRO) Long-Term Debt: kr3.02 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:VIRO ViroGates AS OCSE:VIRO
53 GF Score
Price kr9.50
GF Value kr6.71
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is ViroGates AS Long-Term Debt?

ViroGates AS OCSE:VIRO -5.00% 53 Long-Term Debt is kr3.02 Mil as of Mar. 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 53/100 and a GF Value™ of kr6.71 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ViroGates AS's Long-Term Debt for the quarter that ended in Mar. 2026 was kr3.02 Mil.

ViroGates AS's quarterly Long-Term Debt declined from Sep. 2025 (kr3.63 Mil) to Dec. 2025 (kr3.33 Mil) and declined from Dec. 2025 (kr3.33 Mil) to Mar. 2026 (kr3.02 Mil).

ViroGates AS's annual Long-Term Debt declined from Dec. 2023 (kr5.30 Mil) to Dec. 2024 (kr4.27 Mil) and declined from Dec. 2024 (kr4.27 Mil) to Dec. 2025 (kr3.33 Mil).

ViroGates AS  (OCSE:VIRO) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

ViroGates AS Long-Term Debt Related Terms

ViroGates AS Long-Term Debt Historical Data

* Premium members only.

The historical data trend for ViroGates AS's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViroGates AS Long-Term Debt Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 5.30 4.27 3.33

ViroGates AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.27 3.93 3.63 3.33 3.02
OCSE:VIRO
53GF Score
ViroGates AS OCSE:VIRO
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of kr3.02 Mil mean?
ViroGates AS (OCSE:VIRO) has a Long-Term Debt of kr3.02 Mil as of Mar. 2026.
Is ViroGates AS's Long-Term Debt too high?
ViroGates AS's current Long-Term Debt is kr3.02 Mil. Overall, ViroGates AS has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Long-Term Debt compare to ABT and SYK?
ViroGates AS's Long-Term Debt of kr3.02 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. ViroGates AS's current Long-Term Debt is kr3.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.71, compared to a current price of kr9.50 — trading 41.6% above its estimated fair value. The current Long-Term Debt is kr3.02 Mil. ViroGates AS's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current Long-Term Debt is kr3.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of kr9.50 is trading 41.6% above its estimated GF Value™ of kr6.71. GuruFocus considers ViroGates AS to be Significantly Overvalued.

Key valuation signals for OCSE:VIRO:

  • Long-Term Debt: kr3.02 Mil
  • GF Value™: kr6.71 vs. price of kr9.50 (41.6% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ViroGates AS Business Description

Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
53GF Score

Get the complete analysis for OCSE:VIRO

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.50
Price
kr6.71
GF Value